tbuckley/cabot-search huggingface dataset:
Brief Early Life Angiotensin-Converting Enzyme Inhibition Offers Renoprotection in Sheep with a Solitary Functioning Kidney at 8 Months of Age
Authors: Zoe McArdle, Reetu R. Singh, Helle Bielefeldt-Ohmann, Karen M. Moritz, Michiel F. Schreuder, Kate M. Denton
Journal: Journal of the American Society of Nephrology (2022)

Children born with a solitary functioning kidney (SFK) are predisposed to develop hypertension and kidney injury. Glomerular hyperfiltration and hypertrophy contribute to the pathophysiology of kidney injury. Angiotensin-converting enzyme inhibition (ACEi) can mitigate hyperfiltration and may be therapeutically beneficial in reducing progression of kidney injury in those with an SFK.SFK was induced in male sheep fetuses at 100 days gestation (term=150 days). Between 4 and 8 weeks of age, SFK lambs received enalapril (SFK+ACEi; 0.5mg/kg per day, once daily, orally) or vehicle (SFK). At 8 months, we examined BP, basal kidney function, renal functional reserve (RFR; GFR response to combined amino acid and dopamine infusion), GFR response to nitric oxide synthase (NOS) inhibition, and basal nitric oxide (NO) bioavailability (basal urinary total nitrate and nitrite [NOx]).SFK+ACEi prevented albuminuria and resulted in lower basal GFR (16%), higher renal blood flow (approximately 22%), and lower filtration fraction (approximately 35%), but similar BP, compared with vehicle-treated SFK sheep. Together with greater recruitment of RFR (approximately 14%) in SFK+ACEi than SFK animals, this indicates a reduction in glomerular hyperfiltration-mediated kidney dysfunction. During NOS inhibition, the decrease in GFR (approximately 14%) was greater among SFK+ACEi than among SFK animals. Increased (approximately 85%) basal urinary total NOx in SFK+ACEi compared with SFK animals indicates elevated NO bioavailability likely contributed to improvements in kidney function and prevention of albuminuria.Brief and early ACEi in SFK is associated with reduced glomerular hyperfiltration-mediated kidney disease up to 8 months of age in a sheep model.
LEFT BUNDLE BRANCH AREA PACING FOR CARDIAC RESYNCHRONIZATION THERAPY IN RIGHT BUNDLE BRANCH BLOCK: RESULTS FROM INTERNATIONAL LBBAP COLLABORATIVE STUDY GROUP
Authors: Pugazhendhi Vijayaraman, Oscar Cano, Shunmugasundaram Ponnusamy, Manuel Molina-Lerma, Joseph Yat Sun Chan, Santosh Kumar Padala, Parikshit S. Sharma, Zachary I. Whinnett, Bengt Herweg, Gaurav A. Upadhyay, Faiz Ali Subzposh, Dominik A. Beer, Bednarek Agnieska, Grzegorz Kielbasa, Roderick Tung, Kenneth A. Ellenbogen, Marek Jastrzebski
Journal: Journal of the American College of Cardiology (2022)
PATTERNS OF HEART FAILURE IN PEOPLE WITH HIV
Authors: Karla L. Inestroza, Vanessa Hurtado, Michaela E. Larson, Bertrand F. Ebner, Jelani Kayode Grant, Louis Vincent, Maria Alcaide, Barry Hurwitz, Alexis Powell, Catherine Boulanger, Dushyantha Jayaweera, Claudia A. Martinez
Journal: Journal of the American College of Cardiology (2022)
Sex dimorphism in the tumor microenvironment – From bench to bedside and back
Authors: Fei He, Andrea Rodgers Furones, Nils Landegren, Jonas Fuxe, Dhifaf Sarhan
Journal: Seminars in Cancer Biology (2022)

Cancer represents a significant cause of death and suffering in both the developed and developing countries. Key underlying issues in the mortality of cancer are delayed diagnosis and resistance to treatments. However, improvements in biomarkers represent one important step that can be taken for alleviating the suffering caused by malignancy. Precision-based medicine is promising for revolutionizing diagnostic and treatment strategies for cancer patients worldwide. Contemporary methods, including various omics and systems biology approaches, as well as advanced digital imaging and artificial intelligence, allow more accurate assessment of tumor characteristics at the patient level. As a result, treatment strategies can be specifically tailored and adapted for individual and/or groups of patients that carry certain tumor characteristics. This includes immunotherapy, which is based on characterization of the immunosuppressive tumor microenvironment (TME) and, more specifically, the presence and activity of immune cell subsets. Unfortunately, while it is increasingly clear that gender strongly affects immune regulation and response, there is a knowledge gap concerning differences in sex-specific immune responses and how these contribute to the immunosuppressive TME and the response to immunotherapy. In fact, sex dimorphism is poorly understood in cancer progression and is typically ignored in current clinical practice. In this review, we aim to survey the available literature and highlight the existing knowledge gap in order to encourage further studies that would contribute to understanding both gender-biased immunosuppression in the TME and the driver of tumor progression towards invasive and metastatic disease. The review highlights the need to include sex optimized/genderized medicine as a new concept in future medicine cancer diagnostics and treatments.
Enterotoxigenic <i>Escherichia coli</i> : intestinal pathogenesis mechanisms and colonization resistance by gut microbiota
Authors: Yucheng Zhang, Peng Tan, Ying Zhao, Xi Ma
Journal: Gut Microbes (2022)

Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrhea in children and travelers in developing countries. ETEC is characterized by the ability to produce major virulence factors including colonization factors (CFs) and enterotoxins, that bind to specific receptors on epithelial cells and induce diarrhea. The gut microbiota is a stable and sophisticated ecosystem that performs a range of beneficial functions for the host, including protection against pathogen colonization. Understanding the pathogenic mechanisms of ETEC and the interaction between the gut microbiota and ETEC represents not only a research need but also an opportunity and challenge to develop precautions for ETEC infection. Herein, this review focuses on recent discoveries about ETEC etiology, pathogenesis and clinical manifestation, and discusses the colonization resistances mediated by gut microbiota, as well as preventative strategies against ETEC with an aim to provide novel insights that can reduce the adverse effect on human health.
Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays
Authors: Valentine Marie Ferré, Samuel Lebourgeois, Houssem Redha Chenane, Reyene Menidjel, Christelle Masson, Gilles Collin, Benoit Visseaux, Diane Descamps, Nadhira Fidouh, Charlotte Charpentier
Journal: Journal of Infection (2022)
Surgery for Stress Urinary Incontinence in Women — Improvement but Not a Cure
Authors: Ingrid Nygaard, Peggy Norton
Journal: New England Journal of Medicine (2022)

Historically, women who were considering surgery for stress urinary incontinence faced wide abdominal incisions, inpatient hospitalizations, and a 6-week recovery period. Two decades ago, the introduction of midurethral-sling procedures, which involve passing a small strip of polypropylene mesh under the urethra, resulted in shorter recovery than traditional procedures with similar efficacy. In the first generation of procedures, mesh was placed through the retropubic space. A second-generation approach passed the mesh through the obturator space, to minimize the risk of bowel or bladder injury with trocars inserted into the retropubic space. Extensive evidence, including from 81 trials involving 12,113 women, supports . . .
THE CINCINNATI ATRIAL FIBRILLATION SCORE (CAFS): MULTICENTER VALIDATION OF THE FIRST POLYSOMNOGRAPHY-BASED RISK SCORE FOR PREDICTING INCIDENT ATRIAL FIBRILLATION IN ASYMPTOMATIC AMBULATORY COMMUNITY ADULTS
Authors: Rithika Thirumal, Swati Dey, Benjamin Vaughan, Grace Chen, Sumedha Kappagantula, Eliseo Guallar, Naresh M. Punjabi, Gordon F. Tomaselli, Roger S. Blumenthal, Susan Redline, Richard C. Becker, Hugh Calkins, Wendy S. Post, Steven R. Jones, Deeptankar Demazumder
Journal: Journal of the American College of Cardiology (2022)
Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations
Authors: George Delidakis, Jin Eyun Kim, Katia George, George Georgiou
Journal: Annual Review of Biomedical Engineering (2022)

Interactions between the crystallizable fragment (Fc) domain of antibodies and a plethora of cellular Fc receptors (FcRs) or soluble proteins form a critical link between humoral and innate immunity. In particular, the immunoglobulin G Fc domain is critical for the clearance of target cells by processes that include (a) cytotoxicity, phagocytosis, or complement lysis; (b) modulation of inflammation; (c) antigen presentation; (d) antibody-mediated receptor clustering; and (e) cytokine release. More than 30 Fc-engineered antibodies aimed primarily at tailoring these effects for optimal therapeutic outcomes are in clinical evaluation or have already been approved. Nonetheless, our understanding of how FcR engagement impacts various immune cell phenotypes is still largely incomplete. Recent insights into FcR biology coupled with advances in Fc:FcR structural analysis, Fc engineering, and mouse models that recapitulate human biology are helping to fill in existing knowledge gaps. These advances will provide a blueprint on how to fine-tune the Fc domain to achieve optimal therapeutic efficacy.
HSR22-142: A Review of Lung Cancer Screening Compliance in a Federally Qualified Health Center: Uncovering Unconscious Bias
Authors: Janeen Grant-Sittol, Rani Sittol, Latoya Gayle, Sharde Mcleish, Jodi-Ann Smith, Jason Lofters, Zachary Banbury, Natasha Rastogi, Tanganyika Barnes
Journal: Journal of the National Comprehensive Cancer Network (2022)
Reply to Akin<i>et al</i>.: High Renin Concentrations in Severe COVID-19 Are Indicative for a Hypo–Renin–Angiotensin-System State
Authors: Daniel E. Leisman, Arnav Mehta, B. Taylor Thompson, Nir Hacohen, Michael R. Filbin, Marcia B. Goldberg
Journal: American Journal of Respiratory and Critical Care Medicine (2022)
EFFECT OF BODY MASS INDEX, CHRONIC KIDNEY DISEASE AND SEX IN PATIENTS UNDERGOING PCI: THE OBESITY PARADOX REVISITED
Authors: Tia Bimal, Md Bhuiyan, Umair Ansari, Joanna Fishbein, Samy Selim, Puneet Gandotra, Lawrence Y.C. Ong, Luis Gruberg
Journal: Journal of the American College of Cardiology (2022)
The UK's foreign aid cuts: implications for financing health systems globally
Authors: Kaci Kennedy McDade, Wenhui Mao, Osondu Ogbuoji
Journal: The Lancet Global Health (2022)

The UK is a major provider of official development assistance (ODA) to low-income and middle-income countries (LMICs). The UK recently announced that 102 countries and territories would not receive an ODA budget for the 2021-22 year. Given that the UK is the second largest health ODA donor, these cuts could have serious implications for health systems in LMICs. We aimed to understand how these cuts might affect financing for health systems in countries receiving UK aid.We analysed domestic and external funding for 134 countries that received UK ODA in 2019-20 that had data available. Our goal was to understand the differences between countries that will continue to receive aid in 2020-21 (termed budget safe, n=34) and those that will not (termed budget cut, n=100) and quantify the role the UK plays in financing health systems among both cohorts.53 (53%) of 100 budget-cut countries are LMICs, and sub-Saharan Africa is the region with the largest share (27 countries [27%]). The UK makes up less than 10% of health ODA for almost all budget-cut countries (95 [95%]). The health systems of two budget-cut countries in particular might be faced with financing challenges given their high ratios of UK health aid to domestic government health expenditures: The Gambia (1·24:1) and Eritrea (0·33:1). Although most budget-safe countries are LMICs (26 [76%]), a quarter (eight [24%]) are upper-middle-income or high-income, signalling the geostrategic importance of some wealthier countries to the new UK aid agency. The UK is a large health donor among budget-safe countries: it contributes more than 10% of the health ODA budget in 11 (32%) of 34 countries. Many low-income budget-safe countries in sub-Saharan Africa also exhibit high ratios of UK health ODA to domestic government health expenditures (eg, South Sudan [3·15:1], Sierra Leone [0·48:1], and the Democratic Republic of the Congo [0·34:1]).The 2021-22 UK budget cuts might not be as catastrophic for as many health systems as expected, although some countries might be affected more than others. The UK is a major player in most budget-safe countries, and several countries, particularly low-income countries in sub-Saharan Africa, show high ratios of reliance on UK health aid. Our analysis focused on financing for health systems, but we did not consider the potential effect on funding cuts to health outcomes, analysed potential country responses to these cuts, or propose mechanisms for closing funding gaps.None.
Retraction: Multifunctional Polymeric Nanosystems for Dual‐Targeted Combinatorial Chemo/Antiangiogenesis Therapy of Tumors
Authors: Fatima Zohra Dahmani, Yan Xiao, Juan Zhang, Yao Yu, Jianping Zhou, Jing Yao
Journal: Advanced Healthcare Materials (2022)

Adv. Healthcare Mater. 2016, 5, 1447-1461 DOI: 10.1002/adhm.201600169 The above article, published online on 29 April 2016 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editor-in-Chief, Dr. Uta Goebel, and Wiley-VCH GmbH. Concerns about figures within this article were raised by a reader in 2021, which has led to two Corrections of this article published on 20 January 2021[1] and 21 October 2021,[2] respectively. Subsequently, further concerns were raised about another figure within the article and an investigation of these new concerns indicated that there have been some modifications of the figures that cannot easily be explained. As a result, the journal is unable to determine whether the results and conclusions are valid and so have made the decision to retract the article. [1] F. Z. Dahmani, Y. Xiao, J. Zhang, Y. Yu, J. Zhou, J. Yao, Adv. Healthcare Mater. 2021, 10, 2002223. [2] F. Z. Dahmani, Y. Xiao, J. Zhang, Y. Yu, J. Zhou, J. Yao, Adv. Healthcare Mater. 2021, 10, 2101501.
Abstract P2-13-37: A prospective, open, multi-center clinical study of pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvant treatment for stage II-III HER2-positive breast cancer patients
Authors: Bin Shao, Zhengyan Yu, Yu Wang, Guangcai Zhao, Fei Zhou, Ranmei Wei
Journal: Cancer Research (2022)

Abstract Background: Targeted therapy has significant efficacy in adjuvant and advanced treatment of HER2-positive breast cancer, and it has also promoted its development in neoadjuvant therapy. For HER2-positive breast cancer, chemotherapy with anthracyclines and taxanes combined with trastuzumab targeted therapy is currently the standard regimen for adjuvant or neoadjuvant therapy. On the basis of the preliminary clinical trials, we carried out this study to confirmed efficacy and safety of pyrotinib combined with trastuzumab and nab-paclitaxel as neoadjuvant treatment regimen in patients(pts) with stage II- III HER2-positive breast cancer. Method: In this multicenter, single arm, prospective, open-label phase II study, 46pts with stage II-III HER2-positive breast cancer will be enrolled (in Simon twostages model, 16 pts will be enrolled in the first stage) to receive pyrotinibcombined with trastuzumab and nab-paclitaxel. The inclusion criteria are asflows. (1) female aging from 18 to 75; (2) Eastern Cooperative Oncology Group(ECOG) performance score of 0-1; (3) Life expectancy is no less than 12weeks;(4) Pathologically confirmed HER-2 positive breast cancer;(5) earlystage (T2-3, N0-1, M0) or locally advanced (T2-4, N2, or N3), with tumor sizeno less than 2cm in diameter. All pts will receive pyrotinib (400mg qd) andtrastuzumab: 8 mg/kg for cycle 1 and 6 mg/kg for cycles 2-6, intravenousinfusion, 21 days for 1 cycle, a total of 6 cycles and nab-paclitaxel: 260mg/m2,intravenous infusion, 21 days as a cycle, a total of 6 cycles. The primaryendpoint is pathological complete response rate (pCR: ypT0/is, ypN0), and thesecondary endpoints are disease-free survival time (DFS), objective responserate (ORR), and survival time without distant metastasis (DDFS). Findings: From Nov 2020 to May 2021, a total of 11 pts were enrolled, 4 pts havecompleted surgery and 6 pts could be evaluated for ORR. The pCR rate was50%, ORR was 100% (5 PR, 1CR). Adverse events (AEs) of any garde werediarrhea 11 (100.0%), anorexia and vomiting 8 (72.7%) and rash 4 (36.4%).Garde 3 AEs were diarrhea 3 (27.3%), and there was no grade 4 AEs. Conclusion: Pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvanttreatment for pts with stage II-III HER2-positive breast cancer showedacceptable toxicity and promising efficacy. Citation Format: Bin Shao, Zhengyan Yu, Yu Wang, Guangcai Zhao, Fei Zhou, Ranmei Wei. A prospective, open, multi-center clinical study of pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvant treatment for stage II-III HER2-positive breast cancer patients [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-37.
Stimulation of the hepatoportal nerve plexus with focused ultrasound restores glucose homoeostasis in diabetic mice, rats and swine
Authors: Victoria Cotero, John Graf, Hiromi Miwa, Zall Hirschstein, Khaled Qanud, Tomás S. Huerta, Ningwen Tai, Yuyan Ding, Kevin Jimenez-Cowell, Jacquelyn N. Tomaio, Weiguo Song, Alex Devarajan, Tea Tsaava, Radhika Madhavan, Kirk Wallace, Evelina Loghin, Christine Morton, Ying Fan, Tzu-Jen Kao, Kainat Akhtar, Meghana Damaraju, Linda Barenboim, Teresa Maietta, Jeffrey Ashe, Kevin J. Tracey, Thomas R. Coleman, Dino Di Carlo, Damian Shin, Stavros Zanos, Sangeeta S. Chavan, Raimund I. Herzog, Chris Puleo
Journal: Nature Biomedical Engineering (2022)
CONSTRICTIVE PERICARDITIS MASQUERADING AS HEPATIC AND RENAL DYSFUNCTION AND RESOLVED WITH PERICARDIECTOMY
Authors: Rupinder Buttar, Abdullah Sayied Abdullah, Gurveer khosa, Shaweta Khosa, Bryan E-Xin Tan, Amr Salama, Ahmed Hussein, Bipul Baibhav
Journal: Journal of the American College of Cardiology (2022)
Excessive release of inorganic polyphosphate by ALS/FTD astrocytes causes non-cell-autonomous toxicity to motoneurons
Authors: Cristian Arredondo, Carolina Cefaliello, Agnieszka Dyrda, Nur Jury, Pablo Martinez, Iván Díaz, Armando Amaro, Helene Tran, Danna Morales, Maria Pertusa, Lorelei Stoica, Elsa Fritz, Daniela Corvalán, Sebastián Abarzúa, Maxs Méndez-Ruette, Paola Fernández, Fabiola Rojas, Meenakshi Sundaram Kumar, Rodrigo Aguilar, Sandra Almeida, Alexandra Weiss, Fernando J. Bustos, Fernando González-Nilo, Carolina Otero, Maria Florencia Tevy, Daryl A. Bosco, Juan C. Sáez, Thilo Kähne, Fen-Biao Gao, James D. Berry, Katharine Nicholson, Miguel Sena-Esteves, Rodolfo Madrid, Diego Varela, Martin Montecino, Robert H. Brown, Brigitte van Zundert
Journal: Neuron (2022)
Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells
Authors: Fábio F. Rosa, Cristiana F. Pires, Ilia Kurochkin, Evelyn Halitzki, Tasnim Zahan, Nejc Arh, Olga Zimmermannová, Alexandra G. Ferreira, Hongzhe Li, Stefan Karlsson, Stefan Scheding, Carlos-Filipe Pereira
Journal: Science Immunology (2022)

Type 1 conventional dendritic cells (cDC1s) are rare immune cells critical for the induction of antigen-specific cytotoxic CD8 + T cells, although the genetic program driving human cDC1 specification remains largely unexplored. We previously identified PU.1, IRF8, and BATF3 transcription factors as sufficient to induce cDC1 fate in mouse fibroblasts, but reprogramming of human somatic cells was limited by low efficiency. Here, we investigated single-cell transcriptional dynamics during human cDC1 reprogramming. Human induced cDC1s (hiDC1s) generated from embryonic fibroblasts gradually acquired a global cDC1 transcriptional profile and expressed antigen presentation signatures, whereas other DC subsets were not induced at the single-cell level during the reprogramming process. We extracted gene modules associated with successful reprogramming and identified inflammatory signaling and the cDC1-inducing transcription factor network as key drivers of the process. Combining IFN-γ, IFN-β, and TNF-α with constitutive expression of cDC1-inducing transcription factors led to improvement of reprogramming efficiency by 190-fold. hiDC1s engulfed dead cells, secreted inflammatory cytokines, and performed antigen cross-presentation, key cDC1 functions. This approach allowed efficient hiDC1 generation from adult fibroblasts and mesenchymal stromal cells. Mechanistically, PU.1 showed dominant and independent chromatin targeting at early phases of reprogramming, recruiting IRF8 and BATF3 to shared binding sites. The cooperative binding at open enhancers and promoters led to silencing of fibroblast genes and activation of a cDC1 program. These findings provide mechanistic insights into human cDC1 specification and reprogramming and represent a platform for generating patient-tailored cDC1s, a long-sought DC subset for vaccination strategies in cancer immunotherapy.
Humanitarian Need Jumps in 2022
Authors: Howard D. Larkin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
INTRAVASCULAR LITHOTRIPSY FOR DE-NOVO POST-DILATION OF CORONARY DRUG-ELUTING STENTS
Authors: Rahul Sawhney, Pouyan Arman, Jared Christensen, modar alom, Chadi Dib, Karim Al-Azizi, Sibi P. Thomas, Srinivasa P. Potluri, Sameh Sayfo
Journal: Journal of the American College of Cardiology (2022)
Exerkines in health, resilience and disease
Authors: Lisa S. Chow, Robert E. Gerszten, Joan M. Taylor, Bente K. Pedersen, Henriette van Praag, Scott Trappe, Mark A. Febbraio, Zorina S. Galis, Yunling Gao, Jacob M. Haus, Ian R. Lanza, Carl J. Lavie, Chih-Hao Lee, Alejandro Lucia, Cedric Moro, Ambarish Pandey, Jeremy M. Robbins, Kristin I. Stanford, Alice E. Thackray, Saul Villeda, Matthew J. Watt, Ashley Xia, Juleen R. Zierath, Bret H. Goodpaster, Michael P. Snyder
Journal: Nature Reviews Endocrinology (2022)
PRE-PANDEMIC PREVALENCE AND CONTROL RATES OF HYPERTENSION IN THE USA: NHANES 2017-2020
Authors: Ebad Ur Rahman, Fatima Farah, Muchi Ditah Chobufo, Kanaan Mansoor, Olusola Olubowale, Ebubechukwu Ezeh, Ellen A. Thompson, Mehiar El-Hamdani, Carlos Alberto Rueda Rios, Gregg C. Fonarow, Mark A. Studeny
Journal: Journal of the American College of Cardiology (2022)